Edible cannabis caused more psychiatric and cardiovascular ER visits than expected based on sales volume | Research

The takeaway

Edible cannabis accounted for only 0.32% of Colorado THC sales but 10.7% of cannabis-related ER visits, with higher rates of psychiatric symptoms, intoxication, and cardiovascular problems compared to inhaled cannabis.

Emergency physicians, cannabis regulators, edible manufacturers, and cannabis consumers.

0.32% of sales, 10.7% of ER visits

What the researchers found

Edible cannabis ER visits were disproportionate to sales (10.7% of visits vs 0.32% of THC sales). Compared to inhaled, edible visits had more psychiatric symptoms (18% vs 10.9%), intoxication (48% vs 28%), and cardiovascular symptoms (8% vs 3.1%). Inhaled cannabis visits more often involved cannabinoid hyperemesis (18% vs 8.4%).

Why it matters

This is the definitive study showing edibles are disproportionately represented in ER visits. The disconnect between sales volume and ER visits suggests that edibles pose unique risks, likely related to delayed onset and difficulty dosing.

The numbers in context

9,973 cannabis-coded visits; 2,567 (25.7%) attributable to cannabis; 238 (9.3%) edible-related; edibles: 0.32% of THC sales but 10.7% of attributable visits; psychiatric 18% vs 10.9%; intoxication 48% vs 28%; cardiovascular 8% vs 3.1%.

How the study worked

Chart review of 9,973 ER visits with cannabis ICD codes at a large urban Colorado hospital (2012-2016). 2,567 (25.7%) were at least partially attributable to cannabis. Compared clinical presentations by route of exposure.

What this study cannot tell us

Single academic center in Colorado. Self-reported exposure data. Limited dose information available. Cannot determine whether edible users consumed more THC or were simply more sensitive to its effects.

How to read the evidence

Strong: large retrospective study published in Annals of Internal Medicine with clear, clinically significant findings.

When this study was published

Published in 2019.

The bigger picture

Annals of Internal Medicine publication gives this finding high credibility. The data suggests cannabis policy should differentiate between consumption methods, with edibles requiring specific dosing guidance, labeling, and public education.

Questions still open

Would standardized low-dose edible products reduce ER visits? Are first-time or infrequent users at highest risk from edibles?

Common questions

Are edible cannabis products more dangerous than smoking?

This study found edibles caused a disproportionate number of ER visits relative to their sales volume, with higher rates of psychiatric symptoms, intoxication, and cardiovascular problems compared to inhaled cannabis.

Why do edibles cause more problems?

Edibles have delayed onset (30-120 minutes), making it easy to consume too much before feeling effects. The resulting high blood THC levels can cause intense psychiatric symptoms, severe intoxication, and cardiovascular events.

Read the original research

Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study.

Annals of internal medicine, 170(8), 531-537

View on PubMed ↗Publisher’s paper ↗

Citation

Monte, Andrew A; Shelton, Shelby K; Mills, Eleanor; Saben, Jessica; Hopkinson, Andrew; Sonn, Brandon; Devivo, Michael; Chang, Tae; Fox, Jacob; Brevik, Cody; Williamson, Kayla; Abbott, Diana. (2019). Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study.. Annals of internal medicine, 170(8), 531-537. https://doi.org/10.7326/M18-2809